FDA approves Alembic's Ticagrelor Tablets, 60 mg

Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients

Terumo India launches FineCross M3 micro-guide catheter

FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies

Alembic Pharmaceuticals receives USFDA final approval for Rivaroxaban Tablets USP

Alembic receives USFDA final approval for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg

Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,

Abbott launches intravascular lithotripsy trial aimed at clearing coronary arteries

Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages

Lupin Launches Rivaroxaban Tablets USP, 2.5mg in US

Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals

Zydus receives USFDA approval for Isosorbide Mononitrate Extended-Release, Tablets USP

Isosorbide mononitrate is used to prevent chest pain (angina) in patients with a certain heart condition (coronary artery disease)

Roche launches three new Factor Xa inhibitor coagulation tests

The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention

Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24

The company has received five final approvals

Apollo Hospitals celebrates its leadership position as the largest Cardiac care programme in India

Apollo's unparalleled clinical excellence is built on extensive experience of performing over 300,000 angioplasties and 200,000 cardiac surgeries